Compare TBLA & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBLA | KALV |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | 2000 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 952.2M | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | TBLA | KALV |
|---|---|---|
| Price | $4.93 | $26.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.00 | ★ $32.60 |
| AVG Volume (30 Days) | 2.9M | ★ 5.4M |
| Earning Date | 05-06-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $7.63 | $185.42 |
| Revenue Next Year | $5.25 | $59.23 |
| P/E Ratio | $42.36 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $2.84 | $9.83 |
| 52 Week High | $5.26 | $26.85 |
| Indicator | TBLA | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 68.93 | 74.68 |
| Support Level | $3.86 | $14.25 |
| Resistance Level | $5.26 | $26.85 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 77.26 | 71.05 |
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.